These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25175066)

  • 21. Rituximab treatment for vasculitis.
    Jayne D
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1359-62. PubMed ID: 20671223
    [No Abstract]   [Full Text] [Related]  

  • 22. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
    Rossi S; Motta C; Studer V; Barbieri F; Buttari F; Bergami A; Sancesario G; Bernardini S; De Angelis G; Martino G; Furlan R; Centonze D
    Mult Scler; 2014 Mar; 20(3):304-12. PubMed ID: 23886826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
    Greenberg BM; Graves D; Remington G; Hardeman P; Mann M; Karandikar N; Stuve O; Monson N; Frohman E
    Mult Scler; 2012 Jul; 18(7):1022-6. PubMed ID: 22261118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
    Axelsson M; Mattsson N; Malmeström C; Zetterberg H; Lycke J
    J Neuroimmunol; 2013 Nov; 264(1-2):100-5. PubMed ID: 24125567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation.
    Beltrán E; Obermeier B; Moser M; Coret F; Simó-Castelló M; Boscá I; Pérez-Miralles F; Villar LM; Senel M; Tumani H; Hohlfeld R; Casanova B; Dornmair K
    Brain; 2014 Oct; 137(Pt 10):2703-14. PubMed ID: 25060097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
    Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
    CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data.
    Hawker K
    Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S19-25. PubMed ID: 18388796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
    Harrer A; Tumani H; Niendorf S; Lauda F; Geis C; Weishaupt A; Kleinschnitz C; Rauer S; Kuhle J; Stangel M; Weber F; Uhr M; Linnebank M; Wildemann B; Jarius S; Guger M; Ayzenberg I; Chan A; Zettl U; Wiendl H; Pilz G; Hitzl W; Weber JR; Kraus J
    Mult Scler; 2013 Aug; 19(9):1209-12. PubMed ID: 23093485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebral rituximab uptake in multiple sclerosis: A
    Hagens MH; Killestein J; Yaqub MM; van Dongen GA; Lammertsma AA; Barkhof F; van Berckel BN
    Mult Scler; 2018 Apr; 24(4):543-545. PubMed ID: 28443358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrathecal immune reset in multiple sclerosis: exploring a new concept.
    Bonnan M
    Med Hypotheses; 2014 Mar; 82(3):300-9. PubMed ID: 24417802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential role of B cell-targeted therapies in multiple sclerosis.
    Boster A; Ankeny DP; Racke MK
    Drugs; 2010 Dec; 70(18):2343-56. PubMed ID: 21142258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
    Kimata T; Hasui M; Kino J; Kitao T; Yamanouchi S; Tsuji S; Kaneko K
    Am J Nephrol; 2013; 38(6):483-8. PubMed ID: 24296765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depletion of functionally active CD20+ T cells by rituximab treatment.
    Wilk E; Witte T; Marquardt N; Horvath T; Kalippke K; Scholz K; Wilke N; Schmidt RE; Jacobs R
    Arthritis Rheum; 2009 Dec; 60(12):3563-71. PubMed ID: 19950291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose rituximab is effective in pemphigus.
    Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.
    Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
    Neurology; 2018 Nov; 91(20):e1893-e1901. PubMed ID: 30305449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial.
    Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
    Ophthalmology; 2014 Oct; 121(10):1885-91. PubMed ID: 24953794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MS and the B cell controversy.
    Cross AH; Waubant E
    Biochim Biophys Acta; 2011 Feb; 1812(2):231-8. PubMed ID: 20674743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of recurrent pancreatitis secondary to systemic lupus erythematosus with B-cell depletion therapy.
    Al-Musawi ZS; Nabar UJ
    Arch Iran Med; 2011 Jan; 14(1):66-70. PubMed ID: 21194267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.